Rivaroxaban in Patients Undergoing Hip Arthroplasty in Korean Patients: Implications in Clinical Practice
0
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objective: Currently, rivaroxaban is widely used clinically for thromboprophylaxis after surgery. However, thereare concerns on effectiveness and safety of rivaroxaban for its proper use. We aimed to evaluate the effectivenessand safety of rivaroxaban in orthopaedic patients after total hip replacement surgery in a large medicalcentre after the preferred formulary was switched from enoxaparin to rivaroxaban. Methods: The study wasconducted on the patients who underwent hip arthroplasty surgery at the department of Orthopaedic Surgery atSeoul St. Mary’s Hospital, South Korea. Electronic medical records were retrospectively reviewed to identifypatients treated with rivaroxaban following total hip replacement between February 2011 and March 2012. Evaluation criteria included indications for use, dose, initiation and duration of therapy, drug interactions,adverse reactions, and status of health care reimbursement. The patients who were on enoxaparin were alsoreviewed as a reference. Results: We identified 57 patients who received rivaroxaban and 50 who receivedenoxaparin. All patients were prescribed the drugs for Korean Food and Drug Administration–approved indications. No thromboembolic or bleeding events were observed in either group. However, only 5.3% of rivaroxaban-treated patients had an appropriate length of prophylaxis and only 3.5% began rivaroxaban treatment at therecommended time. Surprisingly, 47.4% of rivaroxaban-treated patients received rivaroxaban despite being ineligiblefor reimbursement benefits. Conclusion: Rivaroxaban was generally well tolerated clinically. However, theduration of treatment, the time of initiation and patient eligibility for reimbursement require improvements,emphasising the need for education which indicates the area of pharmacists’ involvement.
Abstract
Objective: Currently, rivaroxaban is widely used clinically for thromboprophylaxis after surgery. However, thereare concerns on effectiveness and safety of rivaroxaban for its proper use. We aimed to evaluate the effectivenessand safety of rivaroxaban in orthopaedic patients after total hip replacement surgery in a large medicalcentre after the preferred formulary was switched from enoxaparin to rivaroxaban. Methods: The study wasconducted on the patients who underwent hip arthroplasty surgery at the department of Orthopaedic Surgery atSeoul St. Mary’s Hospital, South Korea. Electronic medical records were retrospectively reviewed to identifypatients treated with rivaroxaban following total hip replacement between February 2011 and March 2012. Evaluation criteria included indications for use, dose, initiation and duration of therapy, drug interactions,adverse reactions, and status of health care reimbursement. The patients who were on enoxaparin were alsoreviewed as a reference. Results: We identified 57 patients who received rivaroxaban and 50 who receivedenoxaparin. All patients were prescribed the drugs for Korean Food and Drug Administration–approved indications. No thromboembolic or bleeding events were observed in either group. However, only 5.3% of rivaroxaban-treated patients had an appropriate length of prophylaxis and only 3.5% began rivaroxaban treatment at therecommended time. Surprisingly, 47.4% of rivaroxaban-treated patients received rivaroxaban despite being ineligiblefor reimbursement benefits. Conclusion: Rivaroxaban was generally well tolerated clinically. However, theduration of treatment, the time of initiation and patient eligibility for reimbursement require improvements,emphasising the need for education which indicates the area of pharmacists’ involvement.
참고문헌 (33)
- Hyers TM., "Management of venous thromboembolism : past, present, and future", Arch Intern Med, 163(7), pp.759~768 (2003)
- Kearon C., "Antithrombotic Therapy for VTE Disease : Antithrombotic Therapy and Prevention of Chest Physicians Evidence-Based Clinical Thrombosis(9th ed. ). American College of Practice Guidelines", Chest, 141, pp.e419S~e494S (2012)
- Falck-Ytter Y., "Prevention of VTE in orthopedic surgery patients : Antithrombotic Therapy and Prevention of Thrombosis(9th ed. ). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141(2 Suppl), pp.e278S~325S (2012)
- Eriksson BI., "Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development", Clin Pharmacokinet, 48(1), pp.1~22 (2009)
- Eriksson BI., "Oral anticoagulants in development; focus on thromboprophylaxis in patients undergoing orthopaedic surgery", Drugs, 66(11), pp.1411~1429 (2006)
- Perzborn E., "In vitro and in vivo studies of the novel antithrombotic agent BAY 59-7939 : an oral, direct factor Xa inhibitor", J Thromb Haemost, 3(3), pp.514~521 (2005)
- Depasse F., "Effect of BAY 59-7939–a novel, oral direct factor Xa inhibitor–on clotbound factor Xa activity in vitro", J Thromb Haemost, 3(Suppl 1), pp.P1104~ (2005)
- "Xarelto® (rivaroxaban 10 mg tablets): EU summary of product characteristics"[URL]
- Weinz C., "Metabolism and excretion of rivaroxaban, an oral, direct factor Xa ingibitor, in rats, dogs, and humans", Drug Metab Dispos, 37(5), pp.1056~1064 (2009)
- Kakkar AK., "RECORD2 Investigators. Extended duration rivaroxaban versus shortterm enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty : a double-blind., randomised controlled trial", Lancet, 372(9632), pp.31~39 (2008)
- Eriksson BI., "RECORD1 Study Group. Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty", N Engl J Med, 358(26), pp.2765~2775 (2008)
- Grégoire JP., "Effect of drug utilization reviews on the quality of in-hospital prescribing : a quasi-experimental study", BMC Health Services Research, 6, pp.33~ (2006)
- Garcia DA., "Parenteral Anticoagulants : Antithrombotic Therapy and Prevention of Thrombosis(9th ed. ). American College of Chest Physicians Evidence-Based Clinical Practice Guidelines", Chest, 141, pp.e24S~e43S (2012)
- "Final appraisal determination-Rivaroxaban for prevention of venous thromboembolism after total hip or knee replacement in adults.Issue date" (2009)[URL]
- Phillips MS., "ASHP guidelines on medication-use evaluation", Am J Health Syst Pharm, 53, pp.1953~1955 (1996)
- "Healthcare Benefits Management"[URL]
- Bergqvist D., "Low-molecularweight heparin(enoxaparin)as prophylaxis against venous thromboembolism after total hip replacement", N Engl J Med, 335(10), pp.696~700 (1996)
- Planes A., "Risk of deepvenous thrombosis after hospital discharge in patients having undergone total hip replacement : double-blind randomised comparison of enoxaparin versus placebo", Lancet, 348(9022), pp.224~228 (1996)
- Eikelboom JW., "Extendedduration prophylaxis against venous thromboembolism after total hip or knee replacement : a meta-analysis of the randomised trials", Lancet, 358(9275), pp.9~15 (2001)
- Hull RD., "Extended out-ofhospital low-molecular-weight heparin prophylaxis against deep venous thrombosis in patients after elective hip arthroplasty : a systematic review", Ann Intern Med, 135(10), pp.858~869 (2001)
- O’Donnell M., "Reduction of out-of-hospital symptomatic venous thromboembolism by extended thromboprophylaxis with low-molecular-weight heparin following elective hip arthroplasty : a systematic review", Arch Intern Med, 163(11), pp.1362~1366 (2003)
- "Product information. Clexane Injection®"[URL]
- Dahl OE., "Orthopaedic surgery as a model for drug development in thrombosis", Drugs, 64(Suppl 1), pp.17~25 (2004)
- Agnelli G., "Building effective prophylaxis of deep vein thrombosis in the outpatient setting", Blood Coagul Fibrinolysis, 10(Suppl 2), pp.S29~S35 (1999)
- Xing KH., "Has the incidence of deep vein thrombosis in patients undergoing total hip", knee arthroplasty changed over time? A systematic review of randomized controlled trials, 2008, pp.123(1), 24~34
- Fujita S., "Deep venous thrombosis after total of knee arthroplasty in patients in Japan", Clin Orthop Relat Res, (300), pp.168~174 (2000)
- Won MH., "Prevalence and Risk Factors of Thromboembolism After Joint Arthroplasty Without Chemical Thromboprophylaxis in an Asian Population", JOURNAL OF ARTHROPLASTY, 26(7), pp.1106~1111 (2011), CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS
- Kim YH., "Low incidence of deep-vein thrombosis after cementless total hip replacement", J Bone Joint Surg Am, 70(6), pp.878~882 (1988)
- Yoo MC., "A prospective randomized study on the use nadroparin calcium in the prophylaxis of thromboembolism in Korean patients undergoing elective total hip replacement", Int Orthop, 21(6), pp.399~402 (1997)
- Zindel S., "A multi-perspective cost-effectiveness analysis comparing rivaroxaban with enoxaparin sodium for thromboprophylaxis after total hip and knee replacement in the German healthcare setting", BMC Health Serv Res, 12, pp.192~205 (2012)
- Duran A., "Cost effectiveness of rivaroxaban versus enoxaparin for prevention of post-surgical venous thromboembolism from a U. S. payer’s perspective", Pharmacoeconomics, 30(2), pp.87~101 (2012)
- McDonald H., "Costeffectiveness of rivaroxaban in the prevention of venous thromboembolism : A Canadian analysis using the Ontario Ministry of Health Perspective", J Med Econ, 15(5), pp.817~828 (2012)
- Patel MR., "Rivaroxaban versus warfarin in nonvalvular atrial fibrillation", N Engl J Med, 365, pp.883~891 (2011)